Changes in the Supervisory Board of Avontec GmbH

Former President and CEO of the GSF and also former Chairman and CEO of the Pharmaceuticals Division of the Hoechst AG group elected Chairman of Avontec’s Supervisory Board

Martinsried, (PresseBox) - Avontec GmbH, a Martinsried based biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory diseases today announced that with effect from September 18th, 2007, Prof. Dr. Dr. Ernst Günther Afting, former President and CEO of the GSF and also former Chairman and CEO of the Pharmaceuticals Division of the Hoechst AG group, was elected as new member and Chairman of Avontec’s Supervisory Board. In addition, Mrs. Miki Nakamori, was appointed as new member to the Board. Dr. Jörg Neermann, formerly managing partner of DVC Deutsche Venture Capital and Dr. Hongzhi Bai, VP of Medical Affairs of AnGes MG, have resigned from the company’s Supervisory Board.

Prof. Afting has more than 20 years experience within the pharmaceutical industry. From 1995 to 2005 he was President and Chief Executive Officer of the National Research Center for Environment and Health in Munich, one of the largest German government-funded research centers. Prior to that, he was President and Chief Executive Officer of Roussel Uclaf S.A. in Paris, France, and was also Chairman and CEO of the Pharmaceuticals Division of the Hoechst AG group in Frankfurt. From 1984 to 1989 he was responsible for the worldwide R & D. of the Behring Werke in Marburg, a subsidiary of the Hoechst AG, Frankfurt, where he was appointed as a board member in 1986. Prof. Afting studied Chemistry and Medicine at the Universities of Münster and Freiburg and was tenured professor and head of the Department of Protein - Chemistry in the Institute of Biochemistry at the university of Göttingen until 1984. At present Prof. Afting serves as industrial advisor to venture capital firms and is supervisory board member of several biotech companies in Europe and the USA.

Mrs. Nakamori is in charge of all licensing and business development activities of AnGes since 2001. From 1993 to 2001 Mrs. Nakamori held various positions with increasing responsibilities in the Technology & Business Development Department and the Healthcare Department at Mitsubishi Corporation. Mrs. Nakamori graduated from Kyoto University, Faculty of Agriculture in 1993.

Dr. Thomas Schulze, Chief Executive Officer of Avontec commented: "We are extremely pleased to have gained with Prof Afting an outstanding senior expert from the pharmaceutical industry in our supervisory board. Mrs. Nakamori was already instrumental in building the alliance between Avontec and our Japanese partner Anges MG. I am confident that the exceptional and wide ranging experiences of Prof. Afting and Mrs. Nakamori will be an enormous benefit to guide Avontec’s growth and development into a highly successful biopharmaceutical company. I also wish to thank Dr. Neermann and Dr. Bai for their contribution to Avontec’s past achievements. They have been a great support for us during the past years."

Prof. Afting and Mrs. Nakamori join the members of Avontec’s Supervisory Board who are respectively Dr. Alexander Asam ( DVC Deutsche Venture Capital), Prof. Markus Hecker (University of Heidelberg), Dr. Markus Hosang (BioMedinvest AG), Stefan Keveloh (Innovationskapital Göttingen GmbH) and Dr. Liu (AnGes MG).

Avontec GmbH

AVONTEC is a biopharmaceutical company specialized in the development of novel nucleic acid based therapeutic treatments targeting transcription factors. Transcription factors are the master switches of gene regulation, able to turn genes on and off with exquisite sensitivity. The molecules developed at AVONTEC are designed to specifically attenuate abnormal transcription factor signaling, thereby normalizing the underlying cause of the disease. AVONTEC develops these decoy ODNs as therapeutic agents to treat chronic inflammation. AVONTEC's lead programs, AVT 01 in asthma and AVT 02 in inflammatory skin diseases, have been successfully advanced into Phase IIa clinical trials that are expected to be completed within 2008. In addition, there are several candidates in the pipeline based on AVONTEC's core decoy technology. AVONTEC operates based on a lean business model with a seasoned management team experienced in clinical development.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.